Credit Suisse Group upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a neutral rating to an outperform rating in a research report released on Sunday morning, MarketBeat.com reports. Credit Suisse Group currently has $23.00 price objective on the stock, up from their prior price objective of $20.00.

A number of other equities research analysts have also issued reports on TEVA. Oppenheimer reissued a hold rating on shares of Teva Pharmaceutical Industries in a research note on Thursday, February 8th. Maxim Group reissued a hold rating on shares of Teva Pharmaceutical Industries in a research note on Thursday, February 8th. Cantor Fitzgerald set a $18.00 price target on Teva Pharmaceutical Industries and gave the stock a hold rating in a research note on Thursday, February 8th. Gabelli lowered Teva Pharmaceutical Industries from a buy rating to a hold rating and set a $19.00 price target for the company. in a research note on Friday, February 9th. Finally, Leerink Swann decreased their price target on Teva Pharmaceutical Industries from $17.00 to $16.00 and set an underperform rating for the company in a research note on Friday, February 9th. Ten research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and seven have issued a buy rating to the company. Teva Pharmaceutical Industries has a consensus rating of Hold and an average target price of $21.26.

Shares of Teva Pharmaceutical Industries (TEVA) opened at $18.52 on Friday. Teva Pharmaceutical Industries has a one year low of $10.85 and a one year high of $37.94. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. The stock has a market capitalization of $18,430.00, a P/E ratio of -1.14, a P/E/G ratio of 1.37 and a beta of 0.59.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Thursday, February 8th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 14.52% and a negative net margin of 72.66%. The firm had revenue of $5.46 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same period last year, the company earned $1.38 EPS. Teva Pharmaceutical Industries’s quarterly revenue was down 15.9% compared to the same quarter last year. analysts anticipate that Teva Pharmaceutical Industries will post 2.73 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Exane Derivatives purchased a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at $571,000. Korea Investment CORP increased its holdings in shares of Teva Pharmaceutical Industries by 14.3% in the 3rd quarter. Korea Investment CORP now owns 244,774 shares of the company’s stock valued at $4,308,000 after acquiring an additional 30,674 shares during the period. Private Capital Management Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 51.3% in the 3rd quarter. Private Capital Management Inc. now owns 26,100 shares of the company’s stock valued at $459,000 after acquiring an additional 8,850 shares during the period. Financial Counselors Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 28.8% in the 3rd quarter. Financial Counselors Inc. now owns 181,130 shares of the company’s stock valued at $3,188,000 after acquiring an additional 40,531 shares during the period. Finally, Lockheed Martin Investment Management Co. purchased a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at $317,000. 51.93% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://theolympiareport.com/2018/02/14/teva-pharmaceutical-industries-teva-lifted-to-outperform-at-credit-suisse-group.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.